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Available online 28 November 2012AbstractParacoccidioidomycosis is a granulomatous systemic mycosis endemic in Brazil and other Latin America countries. A DNA vaccine
encoding the immunoprotective peptide 10 (P10) significantly reduced the fungal burden in mice when given prior to or after intratracheal
challenge with Paracoccidioides brasiliensis. Presently, the generation/expansion of CD4þ CD44hi memory T cells as well as Foxp3þ Treg cells
in mice immunized with the DNAvaccine (pcDNA3-P10) before and after infection with P. brasiliensis was investigated. Memory CD4þ CD44hi
T cells simultaneously with Foxp3þ Treg cells increased in the spleens and lungs of pcDNA3-P10 immunized mice on day 0, 30, 60 and 120
postinfection. Histopathology of the lung tissue showed minimal inflammation in immunized mice compared with the unimmunized group,
suggesting a role for regulatory T cells in controlling the immunopathology. The DNA vaccine shows that the repeated immunization generates
memory cells and regulatory T cells that replace the initially protective pro-inflammatory T cells conferring a long term protection while
preserving the integrity of the infected tissue.
 2012 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
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Paracoccidioidomycosis (PCM) is a chronic granulomatous
disease caused by the thermal dimorphic fungus Para-
coccidioides brasiliensis. It is endemic in Brazil, Colombia,
Venezuela and Argentina [1,2]. PCM can inflict a high burden
fungal infection with significant morbidity and mortality* Corresponding author. Instituto de Cieˆncias Biome´dicas II, Departamento
de Microbiologia, Universidade de Sa˜o Paulo, Av. Prof. Lineu Prestes, 1374,
2 andar, Sa˜o Paulo, SP 05508-900, Brazil. Tel.: þ55 11 3091 7351; fax: þ55
11 3091 7354.
E-mail address: taborda@usp.br (C.P. Taborda).
1286-4579/$ - see front matter  2012 Institut Pasteur. Published by Elsevier Ma
http://dx.doi.org/10.1016/j.micinf.2012.11.007associated with it. The treatment for PCM is rather long
(ranging from several months to more than two years)
resulting in a significant number of patients self-discontinuing
treatment and a high loss in patients’ follow up, both associ-
ated with a high rate of disease relapse [3]. Since PCM
primarily affects rural workers, the disease is associated with
significant social and economic factors that mostly affect less
affluent populations [2].
In order to improve the treatment effectiveness, both in
terms of time shortening and protection against the disease, we
have investigated disease modifying peptides. Initially, a 15
amino acid peptide (QTLIAIHTLAIRYAN, named P10
peptide) derived from the immunodominant antigen, gp43, ofsson SAS. All rights reserved.
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protecting mice in a P. brasiliensis intratracheal infection
model by eliciting a protective Th-1 response [4,5]. The P10
peptide, when used in combination with the standard chemo-
therapy regimens for experimental PCM, improved treatment
efficacy with a potential to reduce the time of treatment and
avoid relapses [3]. Similarly, administration of the P10 peptide
entrapped within PLGA in combination with standard
chemotherapy significantly reduced the fungal burden in
a mouse PCM model [6]. This peptide was also administered
admixed with Salmonella enterica FliC flagellin to mice
resulting in significantly enhanced protection against intra-
nasal challenge with P. brasiliensis [7].
The vaccine potential of P10 has also been explored by
inserting the sequence of the P10 peptide into a plasmid
vector (pcDNA3), which proved to be protective in both
prophylactic and therapeutic schemes, as determined by
significant reduction in fungal burden [8]. This result
confirmed a previous one using as insert the whole sequence
of the gp43, which showed a long-term protection of the DNA
vaccine [9]. DNA vaccines present some advantages over the
use of other vaccines. For instance, DNA vaccines can be
rapidly produced, show thermal stability and are easily
produced in large-scale [10].
An effective vaccine must be capable of generating
immunological memory [11]. Memory T cells can be sub-
divided into two subpopulations, T effector-memory (TEM)
and T central-memory (TCM) cells. The first migrate to
inflamed peripheral tissue and are rapidly activated upon
subsequent interaction with the same antigen. TCM cells reside
in the lymphoid tissue, where they replicate and expand,
comprising effector T cells that can subsequently be released
to combat specific pathogens [12,13]. In mice, both subsets
express high amounts of CD44 [14]. Patients with chronic
infectious diseases, such as PCM and leishmaniasis, have
increased numbers of memory T cells even after treatment
[15,16]. Additionally, natural Foxp3þ regulatory T cells are
crucial in maintaining immune homeostasis [17]. For example,
they are necessary to minimize immunopathology during the
host response to pathogens [18] by controlling effector
responses [19]. Depending on the appropriate balance of the
immune response these cells can eventually inhibit the
complete eradication of pathogens from tissues, as demon-
strated in an experimental model of leishmaniasis [20].
In this study, we evaluated the generation/expansion and
protective efficacy of phenotypic CD4þ CD44hi memory T
cells as well as of Foxp3þ Treg cells in mice immunized with
the plasmid DNA encoding the P10 peptide and challenged
with P. brasiliensis yeasts. Our results indicate that the DNA
vaccine elicits a protective immune response while increasing
the percentage of CD4þ CD44hi memory T cells and Foxp3þ
Treg cells in the spleens and lungs of immunized mice before
and after 30, 60 and 120 days of challenge. Our results rein-
force the concept that the presence of T regulatory cells upon
secondary antigen exposure may prevent immunopathology in
the context of vaccination and favor long-term memory as
discussed by Romani and Puccetti [21].2. Materials and methods2.1. Purification of plasmid DNAThe pcDNA3 vector (Invitrogen) used for the expression of
P10 peptide sequence (pcDNA3-P10) has been previously
described [8]. Escherichia coli DH5-a transformed with
pcDNA3 (control, empty vector) or pcDNA3-P10 was grown
in Luria Broth (LB, GIBCO-BRL) containing ampicillin. The
purification of the plasmid DNA was accomplished using the
Endofree Plasmid Purification Kit (QIAGEN AG, Basel,
Switzerland) according to the manufacturer’s instructions.
Plasmid concentration was measured by optical density at 260
and 280 nm and by agarose gel electrophoresis relative to
a standard. Purified preparations were stored in PBS at 20 C
until use.2.2. Fungal strainP. brasiliensis Pb18 yeast cells were used for infections.
Briefly, the yeast cells were maintained on plates containing
solid Sabouraud medium at 37 C. After 7e10 days of growth,
the fungus was transferred to modified Mc VeigheMorton
liquid medium and was cultivated at 37 C for 7 days [22,23].
The yeast cells were then washed 3 times in PBS and their
viability was determined using Trypan Blue. Cultures with
viabilities higher than 90% were utilized.2.3. Animal use and ethics statementBALB/c, 6- to 8-week-old male mice, were bred at the
University of Sa˜o Paulo animal facility under specific
pathogen-free conditions. All animals were handled in accor-
dance with good animal practice as defined by the relevant
national animal welfare authorities and all in vivo testing was
approved by the Institutional Animal Care and Use Committee
of the University of Sa˜o Paulo.2.4. Experimental protocolsTwo different protocols were followed. In the first protocol,
mice were immunized once/week for 4 consecutive weeks
with 50 mg pcDNA3-P10 or control pcDNA3 (empty vector)
or unimmunized. The immunization was intramuscular (i.m.)
in the quadriceps. Seven days after the last immunization, the
mice were euthanized and their spleens were removed for the
analysis of CD4þ CD44hi memory T cells and Foxp3þ Treg
cells. Splenocytes isolated from unimmunized mice were
compared with those from pcDNA3-P10 and pcDNA3-
immunized mice In the second protocol, mice were
submitted to the previously described immunization protocol
and were intratracheally infected with 3  105 P. brasiliensis
yeast cells 7 days after the last immunization. For infection,
mice were anesthetized with ketamine (80 mg/kg) and xyla-
zine (10 mg/kg), and their tracheas were exposed and injected
with yeast cells of the virulent strain Pb 18 in PBS in a total
volume of 50 ml/mice. At day 0, 30, 60 or 120 postinfection,
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collected in order to analyze the populations of CD4þ CD44hi
memory T cells and Foxp3þ Treg cells.2.5. Fungal burden assessmentThe fungal burden was measured in infected mice by CFU
(colony-forming units). At 30, 60 or 120 days after infection,
mice were sacrificed and the lungs were removed. Lung
sections were weighed and homogenized in 1 ml of PBS.
100 ml volumes of the homogenate were inoculated on brain
heart infusion agar plates supplemented with 4% of fetal calf
serum, 5% of P. brasiliensis (strain 192) culture filtrate and
19 UI/ml streptomycin/penicillin. The plates were incubated at
37 C and colonies were counted after 20 days.2.6. HistopathologyLungs from immunized and infected mice were collected at
30, 60 or 120 days after infection, fixed in 10% formalin, and
embedded in paraffin for sectioning. The sections were stained
with hematoxylineeosin (HE).2.7. Isolation of lung and spleen cellsLungs of mice immunized and challenged with yeast cells
were collected at 30, 60 or 120 days after infection, cut into
small pieces and mechanically homogenized in PBS. The
homogenate was filtered in gauze to remove major tissue
fragments and then centrifuged at 1400  g at 4 C for 10 min
[24,25]. Spleens were also excised and submitted to mechan-
ical disruption in sterile RPMI 1640 followed by red blood
cells lysis using RBC Lysis Buffer (e-Bioscience, EUA).2.8. Splenocyte proliferation assaysIsolated splenocytes were counted in 0.1% Trypan blue and
the cells were plated in 96-well flat-bottom plates at
a concentration of 4  105 cells/well in RPMI 1640 supple-
mented with 20 mM NaHCO3, 10 mM HEPES, 100 U of
penicillin/ml, 100 mg of streptomycin/ml, 2 mM L-glutamine,
50 mM b-mercaptoethanol, 5 mM sodium pyruvate, 100 mM
nonessential aminoacids and 10% fetal calf serum. The spleen
cells were cultured for 144 h at 37 C under 5% CO2 with the
P10 peptide (1.02  102 mM) as a recall antigen [4].
Controls included cells stimulated with Concanavalin A (1 mg/
well) or medium alone. Experiments were performed in trip-
licates. At the end of the incubation period, 50 ml of MTT
(1 mg/ml) was added to each well, and the plates were incu-
bated for another 4 h followed by the addition of 100 ml/well
of 0.04 N isopropanol-HCl to dissolve the formazan crystals.
The absorbance was measured at 596 nm in a microplate
reader, according to a protocol adapted from Mosmann [26].
Culture supernatants were collected for cytokine detection.2.9. Flow cytometrySpleen and lung cells were prepared as follows. Fc recep-
tors were blocked using anti-CD16/CD32 (clone 24G2) for
30 min at 4 C in PBS containing 3% fetal calf serum. The
cells were stained for surface molecules using the following
mAbs: FITC-conjugated anti-CD4 (clone RM4-5) and PE-
conjugated anti-CD44 (clone IM7) (0.5 mg/106 cells; Bd
Pharmingen, San Diego, CA) and incubated for 30 min at
4 C. Cells were washed with PBS containing 3% fetal calf
serum and suspended in 300 ml of this buffer. For staining of
Foxp3, cells were fixed and permeabilized using anti-mouse/
rat Foxp3 Staining Set (e-Bioscience, San Diego, CA) and
labeled with PE-conjugated anti-Foxp3 (clone FJK-16s,
0.75 mg/106 cell). Cell acquisition was performed using
a FACScalibur flow cytometer (Pharmingen, BD) and the data
collected was analyzed using FlowJo 7.2.4 software (TreeS-
tar). FMO tubes were used as additional controls.2.10. Cytokine detection in culture supernatantsCulture supernatants were analyzed for the presence of
IFN-g, IL-12, TNF-a, IL-10, IL-4 and TGF-b using ELISA
kits (Pharmingen, San Diego, CA) according to the manu-
facturer’s protocol. Standard curves were made using
recombinant cytokines provided in the kit.2.11. Statistical analysisData are presented as mean values  SEM and were
compared using one-way ANOVA test with Tukey multiple
comparisons post-test. The unpaired Student’s t test with
Welch’s correction (two-tailed) was used for comparison of
two groups when the data met the assumption of t tests. The
Graphpad Prism 5.0 software was used for the analysis. P
values were considered significant when p < 0.05.3. Results3.1. Immunization with pcDNA3-P10 significantly
decreased pulmonary fungal burden in immunized mice
and reduced pulmonary tissue damageWe have previously shown that the DNA vaccine encoding
P10 in experimental paracoccidioidomycosis [8] rendered
a significant protective effect. Here, we show the effect of
this vaccine on pulmonary fungal burden after 30, 60 and 120
days of infection (Fig. 1A). Although the empty vector
pcDNA3 was partially protective, the pcDNA3-P10 was
significantly more potent on every time interval examined.
Histological analyses revealed that immunization with
pcDNA3-P10 reduced the fungal burden and concomitantly
promoted resolution of the pathological alterations induced
by the infection (Fig. 1). On day 30 postinfection, the tissue
samples harvested from both pcDNA3-P10 and pcDNA3-
immunized mice displayed dense inflammatory infiltrates.
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Fig. 1. Reduction of pulmonary fungal burden in pcDNA3-P10-immunized mice. A) Mice experimental groups (unimmunized, pcDNA3-P10 and pcDNA3) were
challenged intratracheally with 3  105 P. brasiliensis yeast cells and sacrificed after 30, 60 and 120 days of infection. Data represent two independent experiments
(total of 10 animals) with similar results and are shown as means  SEM. * ( p < 0.05) and ** ( p < 0.01) comparing pcDNA3-P10 to pcDNA3 group; ##
( p < 0.01) and ### ( p < 0.001) comparing pcDNA3-P10 to the unimmunized group. Histology of lung sections of BALB/c mice immunized with either pcDNA3
or pcDNA3-P10 and intratracheally challenged with 3  105 yeast cells of P. brasiliensis and sacrificed after 30, 60 and 120 days of infection. Unimmunized and
uninfected mice (B, E and H). pcDNA3-immunized mice at (C) 30, (F) 60 or (I) 120 days after challenge. pcDNA3-P10-immunized mice at (D) 30, (G) 60 and (J)
120 days after challenge. Slides were stained with hematoxylineeosin; magnification 400.
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cells visualized in the tissues (Fig. 1C), whereas rare yeast
cells were present in tissues from pcDNA3-P10-immunized
mice (Fig. 1D). Whereas tissue sections from pcDNA3-
immunized mice displayed persistent dense and focal
inflammation at 60 and 120 days after infection, respectively
(Fig. 1F and I), lung sections from pcDNA3-P10-immunized
mice showed progressively clear alveolar airspaces and
minimal inflammation (Fig. 1G and J). Thus, the immuniza-
tion with pcDNA3-P10 conferred protection against P. bra-
siliensis infection with a reduction in the fungal burden and
a rapid resolution of pulmonary inflammation.3.2. Immunization with pcDNA3-P10 enhances
splenocyte proliferation and induces a T-cell immune
responseWe cultivated splenocytes from pcDNA3-P10 and
pcDNA3-immunized mice and stimulated them with the P10
peptide in vitro to assess the effect of immunization on cellular
proliferation. Prior to infection (day 0), the pcDNA3-P10-
immunized animals showed increased splenocyte prolifera-
tion when compared to splenocytes from unimmunized group
or from pcDNA3-immunized mice (Fig. 2). Similar results
were obtained when the same experiment was performed with
Fig. 2. Immunization with pcDNA3-P10 and P10 induced proliferation of
splenocytes. Splenocytes from unimmunized, pcDNA3-P10 or pcDNA3-
immunized mice were isolated on day 0, 30, 60 and 120 postinfection and
incubated with the P10 peptide or medium alone for 144 h. Splenocytes
cultured with Concanavalin A for 48 h gave mean absorbance values of 0.508
(data not shown). The data represent two independent experiments (total of 5
animals per group) with similar results and are shown as triplicate
means  SEM. **( p < 0.01) and *** ( p < 0.001) comparing pcDNA3-10 to
the unimmunized group. ### ( p < 0.001) comparing pcDNA3-10 to pcDNA3.
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pcDNA3-P10-immunized mice after 30, 60 or 120 days of
infection. Interestingly, at 60 days after infection the spleno-
cyte proliferation decreased to the level obtained at day 0 and
then the proliferation increased to the highest level on day 120.
We also analyzed the splenocyte culture supernatants in
order to evaluate the pattern of cytokines released after in vitro
stimulation with P10 peptide as a recall antigen (Table 1). The
immunization with pcDNA3-P10 resulted in an increase
especially for IFN-g and IL-12 but IL-10 and TNF-a also
showed a small increase. When compared to unimmunized
control groups the IFN-g levels remained high in splenocytesTable 1
Cytokine levels in splenocyte culture supernatants from unimmunized, pcDNA3-P
Cytokine Experimental groups (five mice per group) Cytokine level (pg
0 day inf.
IFN-g (pg/mla) Unimmunized 4070  100
pcDNA3-P10 29410  20 (***)
pcDNA3 10110  44 (**)
IL-12 (pg/ml) Unimmunized 4355  10
pcDNA3-P10 5680  1250 (**)
pcDNA3 5248.5  125.5 (*
TNF-a (pg/ml) Unimmunized 488.57  14.28
pcDNA3-P10 679.04  14.29
pcDNA3 605.08  7.32
IL-4 (pg/ml) Unimmunized 67.84  5.39
pcDNA3-P10 72.46  2.31
pcDNA3 70.59  2.06
IL-10 (pg/ml) Unimmunized 1775  15.62
pcDNA3-P10 2281.25  9.37 (*
pcDNA3 1907.36  53.04
TGF-b (pg/ml) Unimmunized 2790.5  185.5
pcDNA3-P10 3165  89
pcDNA3 3092  84
*p < 0.05; **p < 0.01; ***p < 0.001 comparing pcDNA3-P10 and pcDNA3-imm
a pg/ml indicates picograms per milliliter.
b inf. Infection.isolated from both pcDNA3 and pCDNA3-P10-immunized
mice after 30, 60 and 120 days of infection. In contrast,
IFN-g levels in unimmunized mice decreased after infection.
In pcDNA3-immunized mice, IFN-g levels increased after
immunization and on days 30 and 60 after infection to a lesser
degree than in the pcDNA3-P10-immunized mice. Both
pcDNA3-P10 and pcDNA3 immunizations similarly induced
the release of IL-12 but, although pcDNA3 treatment main-
tained the same response after 30 and 60 days of infection,
pcDNA3-P10 immunization led to further increase in IL-12 at
all time intervals after infection. Although TNF-a levels
decreased in unimmunized or pcDNA3-immunized mice after
infection, the pcDNA3-P10-immunized animals maintained
the production of this cytokine even 60 days after infection.
IL-4 levels were reduced in both pcDNA3-P10 and pcDNA3-
immunized mice at 30 and 60 days postinfection, more
significantly in the mice that received pcDNA3-P10. Inter-
estingly, IL-4 levels significantly increased compared to
controls in both treatment groups on day 120. The levels of IL-
10 were higher in the pcDNA3-P10-immunized group at all
time points analyzed compared to the unimmunized and
pcDNA3 groups. The IL-10 levels increased relative to
controls on day 120 after infection. TGF-b levels were similar
in all groups. Taken together, these results indicate that
immunization with pcDNA3-P10 can augment the prolifera-
tive capacity of splenocytes before and after infection, and
demonstrate induction of a T-cell immune response charac-
terized by the secretion of high levels of IFN-g and IL-12.3.3. Phenotypic CD4þ CD44hi memory T cells are
generated during immunization with pcDNA3-P10pcDNA3-P10 immunization was able to generate memory
T cells as analyzed by determining the presence of CD4þ10 or pcDNA3-immunized mice after stimulation with P10 peptide.
/ml)
30 days inf.b 60 days inf. 120 days inf.
1102.5  12.5 50  40 2805  15
30110  346 (***) 32220  130 (***) 21540  210 (***)
11102  663 (**) 1660  90 (**) 2560  170
1602.5  362.5 155  50 3530  175
21606.5  733.5 (***) 16830  225 (***) 14680  425 (***)
) 5732  300 (*) 6580  125 (**) 3530  75
87. 49  11.15 7.62  4.76 160  4.76
679.49  86.49 (**) 688.57  9.52 (***) 214.76  7.14
275.81  24.94 281.42  11.90 (**) 190.95  11.9
99.2  1.56 119.38  1.53 84.76  5.38
2.99  0.21 (***) 3.23  0.77 (***) 154  5.38 (**)
23.72  1.74 (***) 31.69  4.61 (***) 255.53  5.38 (***)
830.63  30.18 787.50  15.62 881.25  15.62
*) 2048. 47  204.52 (*) 1118.75  9.37 (***) 3621.88  37.5 (***)
1371.28  172.64 837.50  28.12 2053.13  37.50 (**)
2928  159 2965.5  135.5 2887  314
3874.5  112.5 3408.5  121.5 2408.5  78.5
3209.5  222.5 2651.5  292.5 3344.5  314.5
unized mice to unimmunized animals.
186 J. de Amorim et al. / Microbes and Infection 15 (2013) 181e191CD44hi T cells in spleens by flow cytometry. The percentage
of CD4þ CD44hi T cells in the spleens from pcDNA3-P10-
immunized mice progressively increased over the course of
infection and the percentages were significantly greater
compared to unimmunized and pcDNA3-immunized mice
(Fig. 3A and C). On days 60 and 120 after infection, pcDNA3-
immunized mice also had higher percentages of these cells
compared to controls. Similarly, CD4þ CD44hi T cells in the
lungs of pcDNA3-P10-immunized animals increased over the
course of the infection compared to unimmunized and
pcDNA3-immunized groups (Fig. 3B and D) however, only at
120 days after infection the difference was statistically
different. Memory T cells also significantly increased during
infection in mice treated with pcDNA3 compared to unim-
munized group. Thus, immunization with pcDNA3-P10 is
capable of inducing phenotypic CD4þ CD44hi memory T not
only in the spleen but also in the lungs. The ability of empty
vector to stimulate the immune response is probably induced
by CpG sequences. In the beginning (30 and 60 days)
a mixture of protective pro-inflammatory cells and Treg cells
are present at higher concentration than memory cells. These
experiments showed the importance of the inclusion of a group
with long-term infection (120 days).3.4. Foxp3þ Treg cells are generated/expanded during
immunization with pcDNA3-P10 and are recruited to the
lungs during infection with P. brasiliensisWe evaluated the expansion of Foxp3þ Treg cells before
and after infection with P. brasiliensis with and without
immunization using pcDNA3 or pcDNA3-P10. In unimmu-
nized mice, the percentage of Treg cells in the spleen
progressively expands. Immunization with plasmid DNA
encoding P10 peptide sequence increased the percentage of
CD4þ Foxp3þ T cells in the spleen compared to unimmunized
(immunized only and at 30 and 120 days after infection) and
pcDNA3-immunized (immunized only and at 30 days after
infection) groups (Fig. 4A and D). The percentage of CD4þ
Foxp3þ T cells in pcDNA3-P10-immunized mice was higher
at all time points examined, although the difference was
greatest on day 0 and day 30 after infection and the percentage
of these cells diminished after this time point. The pcDNA3-
immunized group also had an increase in the percentage of
CD4þ Foxp3þ T cells compared to the unimmunized group,
but was less than the percentage in the pcDNA3-P10-
immunized mice until day 120. In the short time protocols
we observed again a mixed response, the presence of Treg at
the beginning of immunization followed by reduction appears
to be important for reduction of tissue injury.
In contrast to the results in the spleen, pcDNA3-immunized
mice had a high percentage of CD4þ Foxp3þ T cells in their
lungs when compared to unimmunized and pcDNA3-P10-
immunized mice after 30 and 60 days of infection (Fig. 5A
and B). The mice immunized with pcDNA3-P10 also had
increased percentages of the CD4þ Foxp3þ T cell compared to
unimmunized mice on days 30 and 60 post-infection (Fig. 5A
and B). The lower levels of Treg cell in the lung of pcDNA3-P10-immunized mice in relation to pcDNA3-immunized mice
is may be mediated by cytokines produced by pro-
inflammatory cells induced by the presence of P10.
4. Discussion
The need for fungal vaccines has been well defined [27].
DNA vaccines are attractive for combating mycoses since they
are capable of eliciting humoral and cellular immune
responses, with the latter being particularly important in
fungal infections [27] including PCM [28]. Prior experimental
vaccines with efficacy against P. brasiliensis have used
plasmid DNA encoding either the gp43 [9] or the hsp65 gene
from M. leprae [29]. We hypothesized and indeed demon-
strated that a plasmid DNA containing the minigene encoding
the P10 peptide, which includes the T-cell epitope of gp43 [4],
could be highly effective against this deep mycosis [8].
Previously, we have shown that administration of synthetic
P10 reduced the time of treatment of experimental PCM,
acting as an adjuvant to standard chemotherapy [3].
Animals immunized with the pcDNA3-P10 showed
a significant reduction in the pulmonary fungal burden when
compared to unimmunized and pcDNA3-immunized mice
after 30, 60 and 120 days of intratracheal infection. Further,
immunization with pcDNA3-P10 significantly enhanced the
histological resolution of the pulmonary infection.
Splenocytes from mice immunized with pcDNA3-P10
rather than pcDNA3 and unimmunized controls, isolated
before or after infection and stimulated in vitro with P10,
showed increased cellular proliferation at all time points.
Noteworthy is that such proliferative response remained
significantly high through 120 days of infection demonstrating
the durability of the vaccine’s effect. The high levels of IFN-g
in the culture supernatants of pcDNA3-P10-treated spleno-
cytes compared to the other experimental groups at all time
points also supports the protective capacity of our vaccine, as
this cytokine activates alveolar macrophages, which are crit-
ical in the resistance to PCM [30,31]. IL-12 and TNF-a have
also been associated with resistance to PCM [32,33], and the
levels of these cytokines were also high in the mice immu-
nized with pcDNA3-P10 compared to the other groups. In
contrast, the pcDNA3-P10-immunized mice displayed
extremely low levels of IL-4, which is associated with
susceptibility to PCM [34]. The pattern of cytokines released
by the splenocytes from mice immunized with pcDNA3-P10 is
consistent with a Th1-biased T-cell immune response, which is
predictive of a good clinical response [3,9,29].
Culture supernatants of splenocytes isolated from mice
immunized with pcDNA3-P10 contained IL-10 at higher
levels than the control group. In an experimental model of
leishmaniasis, IL-10 is associated with persistence of the
parasite [35] and anti-inflammatory responses. Notably, IL-10
modulates the differentiation process of regulatory T cells
[36], and the increased secretion of IL-10 in the pcDNA3-P10-
immunized group could be related to the high frequency of
regulatory T cells. Mice with chronic leishmaniasis or schis-
tosomiasis generate nTreg cells that are capable of secreting
Fig. 3. Immunization with pcDNA3-P10 generates phenotypic CD4þ CD44hi memory T cells in the spleen and lung. (A) Percentage of CD4þ CD44hi cells in the
spleens and (B) lungs of unimmunized, pcDNA3-P10 or pcDNA3-immunized mice on day 0, 30, 60 and 120 postinfection with 3  105 P. brasiliensis yeast cells.
Numbers represent the means of five mice per group. The data represent two independent experiments with similar results and are shown as means  SEM. *
( p < 0.05), ** ( p < 0.01) and *** ( p < 0.001) comparing pcDNA3 or pcDNA3-P10 to the immunized group. # ( p < 0.05) and ## ( p < 0.01) comparing pcDNA3
to pcDNA3-P10. Representative counter plots demonstrate one of the experiments performed for spleen (C) and lungs (D).
187J. de Amorim et al. / Microbes and Infection 15 (2013) 181e191IL-10 when stimulated with recall antigens [37,38]. In chronic
infections, Foxp3þ nTreg cells suppress effector immune
responses against diverse pathogens, including Candida albi-
cans, while contributing to their persistence in the host [39]. Inthe present study, we show that intratracheal infection by P.
brasiliensis resulted in the generation/expansion of Foxp3þ
Tregs in the spleen and lungs of infected mice when compared
to controls after 30 days of infection. Generation/expansion of
Fig. 4. Immunizationwith pcDNA3-P10generates/expandsCD4þFoxp3þTcells. (A) Percentage ofCD4þFoxp3þ cells in the spleens of unimmunized, pcDNA3-P10
or pcDNA3-immunized mice on day 0, 30, 60 and 120 postinfection with 3 105 P. brasiliensis yeast cells. Numbers represent the means of five mice per group. The
data represent two independent experiments with similar results and are shown as means SEM. * ( p < 0,05) and ** ( p < 0.01) for pcDNA3-P10 in relation to the
unimmunized group. # ( p< 0.05) and ## ( p< 0.01) for pcDNA3-P10 compared to pcDNA3 group. (B) Splenocytes frommice belonging to the experimental groups
were gated on lymphocytes via their forward (FSC) and side scatter (SSC) properties (C) and gated onCD4þT cells. (D). Representative histograms demonstrate one of
the experiments performed. The filled histograms correspond to the experimental groups and the empty histograms correspond to control FMO.
188 J. de Amorim et al. / Microbes and Infection 15 (2013) 181e191Treg cells has been shown in a broad variety of infectious
diseases, as by viruses, bacteria, fungi or parasites [40e42]. In
PCM, the generation of cells with the ability to suppress an
effector immune response was first reported in 1988 and the
effect was thought to correlate with the severity of the disease
[43]. A study performed with patients suffering from the
chronic form of PCM revealed that these patients had a high
frequency of nTregs cells in PBMC and lesions when
compared to healthy individuals [44].
The impact ofDNAvaccination on the long-termmemory and
the production ofFoxp3þTreg cells,was examined in immunizedand control animals before and after infectionwithP. brasiliensis.
Generally, prevention of T-regulatory cells induction seems to be
associated with protective immunity. Their presence, however,
concomitant with repeated antigen exposure may prevent
immunopathology and favor long-term memory [21].
In the present work we observed a high frequency of
Foxp3þ Treg cells in the spleens of mice immunized with
pcDNA3-P10 compared to unimmunized and pcDNA3-
immunized animals at all time points examined. In the lungs
of these mice, we found that treatment with pcDNA3 induced
a greater increase in Foxp3þ Tregs than upon pcDNA3-P10
Fig. 5. CD4þ Foxp3þ T cells are recruited to the lungs during the course of
chronic infection with PCM. Percentage of CD4þ Foxp3þ cells in the lungs of
unimmunized, pcDNA3-P10 or pDNA3-immunized mice on day 0, 30, 60 and
120 postinfection with 3  105 P. brasiliensis yeast cells. Numbers represent
the means of five mice per group. The data represent two independent
experiments with similar results and are shown as means  SEM. * ( p < 0.05)
and ** ( p < 0.01) comparing pcDNA3 or pcDNA3-P10 to the unimmunized
group. # ( p < 0.05) comparing pcDNA3 to pcDNA3-P10. (B) Representative
histograms demonstrate one of the experiments performed. The filled histo-
grams correspond to the experimental groups and the empty histograms
correspond to control FMO.
189J. de Amorim et al. / Microbes and Infection 15 (2013) 181e191immunization, although the vaccine with P10 generated more
of these cells relative to non-immunized animals. Other
studies have shown that Foxp3þ Treg cells are recruited to the
lungs of mice with pneumocystosis and aspergillosis [45,46].
The Foxp3þ Tregs cells were most likely generated in the
secondary lymphoid tissues at the immunization stage with
pcDNA3-P10 and recruited to the lungs after the challenge
with P. brasiliensis where they suppress effector immune
responses, thus reducing tissue damage. This hypothesis is
reinforced by the histopathology which showed that pcDNA3-
P10-immunized mice largely resolved their pneumonias
within 60 days of infection. Treg cells are typically recruited
to the lungs and other organs in response to CCL4, especially
on antigen-presenting cells [47], and an efficient Treg
recruitment to the lung in response to P. brasiliensis infection
depends on CCR5 [25].The intimate relation between Treg cells and immunological
memory was first characterized in an experimental model of
Leishmania major infection, where the presence of nTreg cells at
the sites of infection prevented the clearance of the parasitewhile
maintaining the immunological memory and, therefore, pre-
venting re-infection [48]. As described, Treg cells can interfere
with the host effector response and prevent the sterile cure of
diverse pathogens, as demonstrated with viruses and parasites
[37,49]. Nevertheless, Tregs are involved in the maintenance of
immunological memory, once the pathogen is controlled, such as
in a granuloma, but not eliminated. Presently, we found a high
frequency of phenotypic CD4þ CD44hi memory T cells in the
spleens and lungs of mice immunized with pcDNA3-P10
compared to control and pcDNA3 groups before and after the
infection at all time points. The lower numbers of Foxp3þ Treg
cells in the lungs of pcDNA3-P10-immunized animals could be
associated with a more effective response of the CD4þ CD44hi
memory T cells in these mice. Interestingly, memory T cell
expansion was also noted in spleens during infection of unim-
munized animals indicating that P. brasiliensis infection does not
suppress the generation of memory T cells. The maintenance of
immunological memory seems to be closely related to the pres-
ence of Treg cells. The pcDNA3-immunized group had lower
percentages of phenotypic CD4þ CD44hi memory T cells in the
lungs, but higher percentages of Foxp3þ Treg cells. In fact, Treg
cells can suppress other cells like CD4þ CD44hi T cells, by
inducing apoptosis mediated by cytokine deprivation [50].
In summary, our results demonstrate that vaccinationwith the
plasmid DNA encoding the P10 peptide successfully protects
mice against intratracheal infection with P. brasiliensis while
promoting the generation of phenotypic CD4þ CD44hi memory
T cells simultaneouslywith the generation/expansion of Foxp3þ
Treg cells. Although the generation of Foxp3þ Treg presumably
negatively impacts on pathogen clearance, these cells contribute
to reduce the immunopathology and favor long-term memory.
The data strongly supports that the pcDNA3-P10 vaccine is an
excellent candidate for combating P. brasiliensis when used in
a therapeutic protocol.
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